Telix Pharmaceuticals Ltd（TLX）财务数据TLXTelix Pharmaceuticals Ltd

Evaluating the bottom line, Telix Pharmaceuticals Limited maintains a gross margin of 52.15%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of 7.14%, provide a clear picture of how effectively TLX converts its operational activities into shareholder value.

In the context of the broader market, TLX competes directly with industry leaders such as DNTH and EWTX. With a market capitalization of $3.10B, it holds a significant position in the sector. When comparing efficiency, TLX's gross margin of 52.15% stands against DNTH's 100.00% and EWTX's N/A. Such benchmarking helps identify whether Telix Pharmaceuticals Limited is trading at a premium or discount relative to its financial performance.

Telix reported Q3 2026 revenue of $245 million, a 19% increase year-over-year, showing strong demand for its products. However, its forward P/E ratio of 140.8451 raises concerns about valuation.